Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9552831 | 0.83 | SLC6A3 (0.41) | SLC6A3CYP19A1SLC6A4 | |
| SCHEMBL9553615 | 0.79 | SLC6A3 (0.42) | SLC6A3CYP19A1SLC6A4 | |
| SCHEMBL4820101 | 0.78 | CYP2A6 (0.40) | SLC6A3CYP19A1ICMTSLC6A4CYP2A6 | |
| SCHEMBL2329757 | 0.78 | MMP2 (0.43) | ICMT | |
| SCHEMBL2321584 | 0.77 | SLC6A3 (0.46) | SLC6A3SLC6A4DPP4 | |
| SCHEMBL14861187 | 0.76 | CNR2 (0.43) | SLC6A3CYP19A1SLC6A4CYP2A6 | |
| SCHEMBL16341351 | 0.75 | MMP2 (0.41) | — | |
| SCHEMBL25801663 | 0.75 | CYP2A6 (0.44) | SLC6A3LOXL2CYP19A1ICMTSLC6A4 | |
| SCHEMBL2327941 | 0.75 | KDM1A (0.43) | TRPA1LOXL2CYP19A1ICMTCYP2A6 | |
| SCHEMBL10606455 | 0.74 | SLC6A3 (0.43) | SLC6A3CYP19A1SLC6A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356113-B1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER IP GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2356113-B1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER IP GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | US | disclosed |
| CN-102282143-A | Heterocyclically substituted aryl compounds and application thereof | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2356113-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010054763-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054763-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196964-A1 | HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | SLC6A3 4000/4885TRPA1 4277/4885LOXL2 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.